{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:49:16Z","timestamp":1761518956918},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.diabet.2009.05.003","type":"journal-article","created":{"date-parts":[[2009,9,28]],"date-time":"2009-09-28T08:09:25Z","timestamp":1254125365000},"page":"425-430","source":"Crossref","is-referenced-by-count":6,"title":["Optimal nephroprotection: Use, misuse and misconceptions about blockade of the renin\u2013angiotensin system. Lessons from the ONTARGET and other recent trials"],"prefix":"10.1016","volume":"35","author":[{"given":"J.-M.","family":"Halimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Asmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ribstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2009.05.003_bib1","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2009.05.003_bib2","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2009.05.003_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2009.05.003_bib4","doi-asserted-by":"crossref","unstructured":"The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547\u201359.","DOI":"10.1056\/NEJMoa0801317"},{"key":"10.1016\/j.diabet.2009.05.003_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2009.05.003_bib6","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/sj.bjc.6602102","article-title":"A note on competing risks in survival data analysis","volume":"91","author":"Satagopan","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.diabet.2009.05.003_bib7","first-page":"S107","article-title":"Aging and sodium homeostasis","volume":"37","author":"Mimran","year":"1992","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.diabet.2009.05.003_bib8","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.diabet.2009.05.003_bib9","first-page":"F281","article-title":"Effect of losartan and enalapril on renal adaptation to sodium restriction in rat","volume":"267","author":"Jover","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.diabet.2009.05.003_bib10","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","article-title":"Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats","volume":"96","author":"Menard","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2009.05.003_bib11","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1097\/00004872-200111000-00021","article-title":"Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake","volume":"19","author":"Griffiths","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabet.2009.05.003_bib12","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1681\/ASN.V1081669","article-title":"Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes","volume":"10","author":"Mervaala","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2009.05.003_bib13","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.1987.122","article-title":"Relationship between vascular disease and age-associated changes in the human kidney","volume":"31","author":"Kasiske","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2009.05.003_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/0003-4819-115-7-513","article-title":"Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis","volume":"115","author":"Toto","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2009.05.003_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/ajkd.2002.29909","article-title":"Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels","volume":"39","author":"Komine","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2009.05.003_bib16","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.diabet.2009.05.003_bib17","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2009.05.003_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.2008.204","article-title":"AMADEO investigators","volume":"74","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2009.05.003_bib19","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2009.05.003_bib20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2009.05.003_bib21","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1523-1755.2005.00511.x","article-title":"Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria","volume":"68","author":"Rossing","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2009.05.003_bib22","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1681\/ASN.2005020138","article-title":"Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study","volume":"16","author":"Schmieder","year":"2005","journal-title":"JAm Soc Nephrol"},{"key":"10.1016\/j.diabet.2009.05.003_bib23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archinte.165.8.947","article-title":"The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease in the AASK trial","volume":"165","author":"Lea","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diabet.2009.05.003_bib24","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the RENAAL trial","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2009.05.003_bib25","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1097\/HJH.0b013e328310ddff","article-title":"Albumin excretion is a risk factor for diabetes mellitus in men, independently of initial metabolic profile and development of insulin resistance. The DESIR Study","volume":"26","author":"Halimi","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabet.2009.05.003_bib26","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1111\/j.1600-6143.2008.02308.x","article-title":"Early pulse pressure and low-grade proteinuria as independent long-term risk factors for new-onset diabetes mellitus after kidney transplantation","volume":"8","author":"Roland","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.diabet.2009.05.003_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diabet.2007.06.001","article-title":"Microalbuminuria and urinary albumin excretion: French clinical practice guidelines","volume":"33","author":"Halimi","year":"2007","journal-title":"Diab Metab"},{"key":"10.1016\/j.diabet.2009.05.003_bib28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2009.05.003_bib29","unstructured":"http:\/\/www.kidney.org\/professionals\/physicians\/proteinuria.cfm. accessed February 10th, 2009."},{"key":"10.1016\/j.diabet.2009.05.003_bib30","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703\u201313.","DOI":"10.1136\/bmj.317.7160.703"},{"key":"10.1016\/j.diabet.2009.05.003_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2009.05.003_bib32","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2008.102","article-title":"Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study","volume":"73","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2009.05.003_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1399-0012.2007.00643.x","article-title":"Enalapril\/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial","volume":"21","author":"Halimi","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.diabet.2009.05.003_bib34","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2009.05.003_bib35","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.ki.5002455","article-title":"Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial","volume":"72","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2009.05.003_bib36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","article-title":"Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension","volume":"45","author":"Doulton","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2009.05.003_bib37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2009.05.003_bib38","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(08)60681-9","article-title":"The COOPERATE trial: a letter of concern","volume":"371","author":"Kunz","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2009.05.003_bib39","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2009.05.003_bib40","doi-asserted-by":"crossref","unstructured":"The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545\u201359.","DOI":"10.1056\/NEJMoa0802743"},{"key":"10.1016\/j.diabet.2009.05.003_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2009.05.003_bib42","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2009.05.003_bib43","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":"Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabet.2009.05.003_bib44","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/ndt\/gfm893","article-title":"Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria","volume":"23","author":"Heerspink","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabet.2009.05.003_bib45","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","article-title":"Antiproteinuric effect of oral paricalcitol in chronic kidney disease","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2009.05.003_bib46","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1053\/j.ajkd.2007.12.038","article-title":"Oral Calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial","volume":"51","author":"Szeto","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2009.05.003_bib47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/1043-2760(92)90130-S","article-title":"Prorenin in diabetes mellitus","volume":"3","author":"Halimi","year":"1992","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.diabet.2009.05.003_bib48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1113\/expphysiol.2007.040030","article-title":"Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents","volume":"93","author":"Nguyen","year":"2008","journal-title":"Exp Physiol"},{"key":"10.1016\/j.diabet.2009.05.003_bib49","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1172\/JCI21398","article-title":"Inhibition of diabetic nephropathy by a decoy peptide corresponding to the \u201chandle\u201d region for nonproteolytic activation of prorenin","volume":"114","author":"Ichihara","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2009.05.003_bib50","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","article-title":"Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats","volume":"52","author":"Feldman","year":"2008","journal-title":"Hypertension"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236360900144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236360900144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T09:35:10Z","timestamp":1633944910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S126236360900144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S126236360900144X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2009.05.003","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}